Journals / Meandros Medical And Dental Journal / 2016 / Cilt: 17 - Sayı: 1

Osteoartritte Biyokimyasal Belirteçler: Umut Vadeden Bir Aday Var mı?

Biochemical Markers for Osteoarthritis: Is There any Promising Candidate?

Pages
27–34
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The aim of this paper was to review recent studies on biochemical markers that reflect cartilage, synovial and bone turnover and their clinical use in patients with OA

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Osteoarthritis (OA) is the most common degenerative joint disease.
📊
Key Findings & Data:OA affects millions of individuals each year and becoming the most important cause of pain in geriatric population.
💡
Conclusion & Impact:The aim of this paper was to review recent studies on biochemical markers that reflect cartilage, synovial and bone turnover and their clinical use in patients with OA
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Osteoarthritis (OA) is the most common degenerative joint disease. OA affects millions of individuals each year and becoming the most important cause of pain in geriatric population. Progressive destruction of articular cartilage is one of the prominent features of the disease. The diagnosis of OA is generally based on clinical and radiographical findings, which are insufficient to determine early-stage OA and predict disease course. There is a need for biomarkers that help clinicians early diagnose, assess disease activity, predict prognosis and monitor response to therapy. There are a growing number of publications regarding candidate markers in this field. The aim of this paper was to review recent studies on biochemical markers that reflect cartilage, synovial and bone turnover and their clinical use in patients with OA

Özet

Osteoartrit (OA) en sık rastlanan dejeneratif eklem hastalığıdır. OA her yıl milyonlarca kişiyi etkileyerek, geriatrik yaş grubunun en önemli ağrı sebebi haline gelmektedir. Eklem kıkırdağının ilerleyici hasarı hastalığın en belirgin özelliklerinden biridir. Hastalığın tanısı daha çok klinik ve radyolojik olarak konmaktadır, ancak bu yöntemler erken dönemdeki olguları saptamada ve hastalık son durumunu tahmin etmede yetersiz kalmaktadır. OA hastalarında erken tanı konabilmesi, hastalık aktivitesinin değerlendirilmesi ve tedaviye yanıtın izlenebilmesi için biyokimyasal belirteçlere ihtiyaç vardır. Bu alanda aday biyokimyasal belirteçlerin saptanabilmesi için son dönemde birçok çalışma yayınlanmıştır. Bu yazının amacı kıkırdak, sinovyum ve kemik döngüsünü yansıtan bu biyokimyasal belirteçlerin klinik kullanımları ile ilgili yapılan son dönem çalışmaların derlenmesidir

🔖

Cite This Article

AYDIN, E., TURAN, Y. (2016). Osteoartritte Biyokimyasal Belirteçler: Umut Vadeden Bir Aday Var mı?. Meandros Medical And Dental Journal, Cilt: 17 - Sayı: 1, 27–34. https://ajindex.com/articles/282929

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Vignon E, Garnero P, Delmas P, Avouac B, Bettica P, Boers M, et al; Respect of Ethics and Excellence in Science (GREES): Osteoarthritis Section. Recommendations for the registration of drugs used in the treatment of osteoarthritis: An update on biochemical markers. Osteoarthritis Cartilage 2001; 9: 289-93. Garnero P. Use of biochemical markers to study and follow patients with osteoarthritis. Curr Rheumatol Rep 2006; 8: 37-44.
  2. Lotz M, Martel-Pelletier J, Christiansen C, Brandi ML, Bruyere O, Chapurlat R, et al. Value of biomarkers in osteoarthritis: Current status and perspectives. Ann Rheum Dis 2013; 72: 1756-63.
  3. Hedbom E, Antonsson P, Hjerpe A, Aeschlimann D, Paulsson M, Rosa-Pimentel E, et al. Cartilage matrix proteins. An acidic oligomeric protein (COMP) detected only in cartilage. J Biol Chem 1992; 267: 6132-6.
  4. Wislowska M, Jablonska B. Serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis and knee osteoarthritis. Clin Rheumatol 2005; 24: 278-84.
  5. Cauza E, Hanusch-Enserer U, Frischmuth K, Fabian B, Dunky A, Kostner K. Short-term infliximab therapy improves symptoms of psoriatic arthritis and decreases concentrations of cartilage oligomeric matrix protein. J Clin Pharm Ther 2006; 31: 149-52.
  6. Bjİrnhart B, Juul A, Nielsen S, Zak M, Svenningsen P, Müller K. Cartilage oligomeric matrix protein in patients with juvenile idiopathic arthritis: Relation to growth and disease activity. J Rheumatol 2009; 36: 1749-54.
  7. Hoch JM, Mattacola CG, Medina McKeon JM, Howard JS, Lattermann C. Serum cartilage oligomeric matrix protein (sCOMP) is elevated in patients with knee osteoarthritis: A systematic review and meta-analysis. Osteoarthritis Cartilage 2011; 19: 1396-404.
  8. Hunter DJ, Li J, LaValley M, Bauer DC, Nevitt M, DeGroot J, et al. Cartilage markers and their association with cartilage loss on magnetic resonance imaging in knee osteoarthritis: The boston osteoarthritis knee study. Arthritis Res Ther 2007; 9: R108. Kumm J, Tamm A, Lintrop M, Tamm A. Association between ultrasonographic findings and bone/cartilage biomarkers in patients with early-stage knee osteoarthritis. Calcif Tissue Int 2009; 85: 514-22.
  9. Kumm J, Tamm A, Lintrop M, Tamm A. The value of cartilage biomarkers in progressive knee osteoarthritis: Cross-sectional and 6-year follow-up study in middle-aged subjects. Rheumatol Int 2013; 33: 903-11.
  10. Fernandes FA, Pucinelli ML, da Silva NP, Feldman D. Serum cartilage oligomeric matrix protein (COMP) levels in knee osteoarthritis in a Brazil